Abstract
One of the adverse events of tocilizumab (TCZ) is a transient, dose-dependent neutropenia. The recommendations of the Summary of Product Characteristics state that this neutropenia should be managed according to the absolute neutrophil count (ANC). However, the approach to a patient who had a history of neutropenia induced by previous DMARDs and developed TCZ-induced neutropenia remains unclear. We would like to report a series of four patients with rheumatoid arthritis who developed Grade 2 neutropenia (ANC 1–1.5 × 109/L) following intravenous TCZ treatment at a dose of 8 mg/kg. All of them had a previous history of neutropenia (Grade 2 or Grade 3) due to Etanercept (three patients) and Sulfasalazine (one patient). Therefore, we decided to decrease the TCZ dosage by 10–20 % approximately. Reducing of the dosage did not have any influence on the efficacy of TCZ, and all of our patients remained in clinical remission. The mechanisms underlying neutropenia induced by Tocilizumab, Etanercept and Sulfasalazine are also discussed in this article.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2008;58:887. Erratum in: Arthritis Rheum. 2008;58:887.
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80.
Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23. Erratum in: Ann Rheum Dis. 2009;68:296.
Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609–32.
Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222–32.
Nakamura I, Omata Y, Naito M, et al. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36:459–60.
European Medicines Agency. RoActemra (tocilizumab). Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf. Accessed 1 Sept 2014.
De Benedetti F, Ruperto N, Baildam E, et al. A14: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:S23–4.
Benedetti FD, Rubio-Pérez N, Salazar CD, et al. A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:S67–8.
Montané E, Sallés M, Barriocanal A, et al. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol. 2007;26:1527–9.
Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford). 2008;47:376–7.
Ottaviani S, Cerf-Payrastre I, Kemiche F, et al. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis. Joint Bone Spine. 2009;76:312–3.
Rajakulendran S, Gadsby K, Allen D, et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006;65:1678–9.
Haroon M, Daly M, Harney S. Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia. Clin Rheumatol. 2012;31:151–5.
Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62:764–9.
Szalay B, Acs L, Vásárhelyi B, et al. Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy. J Clin Rheumatol. 2011;17:377–9.
Nagamine R, Chen W, Hara T, et al. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol. 2009;19:348–50.
Nishimoto N1, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426–35.
Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford). 2014;53:1321–31.
Conflict of interest
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shovman, O., Shoenfeld, Y. & Langevitz, P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. Immunol Res 61, 164–168 (2015). https://doi.org/10.1007/s12026-014-8590-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-014-8590-4